Kotak initiates coverage on Mankind Pharma, sees 11% upside. 3 reasons why
Kotak Institutional Equities initiated coverage on Mankind Pharma stock with ‘Add’ rating for a price target of Rs 1,875. The domestic brokerage sees an 11% upside in the counter from current levels. “Mankind Pharma is well-positioned to further leverage its robust marketing prowess and reach. Within branded Rx, we expect a ramp-up of specialty and … Read more